Compare ClearPoint Neuro Inc (CLPT) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Shell PLC — how do they compare? ClearPoint Neuro Inc trades at $14.98 (market cap $454.21M), while Shell PLC trades at $90.05 (market cap $250.44B). The key difference: Shell PLC is far larger — about 551.4× ClearPoint Neuro Inc's market cap, and Shell PLC pays a 3.45% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | SHEL | |
|---|---|---|
Market Cap | $454.21M | $250.44B |
Sector | Health | Energy |
52-Week High | $29.60 | $94.15 |
52-Week Low | $8.66 | $70.31 |
Enterprise Value | $488.79M | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
Shell (SHEL) trades at $90.15, up 0.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.60. Recent Q2 2026 earnings beat estimates with EPS of $3.52 versus $3.23 expected, driven by higher oil prices and strong operational performance. The company maintains solid profitability with a net income margin of 8.76% and ROE of 14.35%, while cash flow from operations reached $42.86B in 2025.
Outlook is positive due to undervaluation (P/E of 10.01), rising oil prices, and strategic asset sales, but risks include commodity volatility and geopolitical tensions affecting energy markets. With 69% of analysts rating it Buy and institutional support, SHEL offers growth potential, though investors should monitor debt levels and global energy demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
